Vericel Corp. (NASDAQ:VCEL)’s share price fell 4.1% during mid-day trading on Thursday . The company traded as low as $2.12 and last traded at $2.12, with a volume of 70,507 shares traded. The stock had previously closed at $2.21.

A number of brokerages have issued reports on VCEL. Needham & Company LLC reissued a “buy” rating and issued a $12.00 target price on shares of Vericel Corp. in a report on Tuesday, April 5th. Bank of America Corp. cut shares of Vericel Corp. from a “buy” rating to a “neutral” rating in a report on Tuesday, April 5th.

The firm’s market cap is $48.68 million. The stock has a 50-day moving average price of $2.37 and a 200 day moving average price of $2.79.

Vericel Corp. (NASDAQ:VCEL) last announced its earnings results on Tuesday, May 10th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.17. The firm earned $14.10 million during the quarter, compared to the consensus estimate of $11.60 million. Equities analysts expect that Vericel Corp. will post ($0.79) EPS for the current fiscal year.

Vericel Corporation (Vericel), formerly Aastrom Biosciences, Inc develops patient-specific expanded cellular therapies for use in the treatment of patients with diseases and conditions. Vericel markets two autologous cell therapy products in the United States: Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns greater than or equal to 30% of total body surface area (TBSA).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.